4 completed, 3 active not recruiting, 1 recruiting. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 4, Active not recruiting 3, Recruiting 1 |
Follow olezarsen: new trials by email Literature Review of olezarsen trials Research Report on olezarsen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants Olezarsen - Familial Chylomicronemia Syndrome | Phase 3 | Recruiting | Ionis Pharmaceuticals, Inc. | 12 | 2026-07-31 | 2026-10-08 |
| CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) Olezarsen - Severe Hypertriglyceridemia | Phase 3 | Active not recruiting | Ionis Pharmaceuticals, Inc. | 885 | 2022-12-13 | 2025-12-01 |
| A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia Olezarsen, Placebo - Hypertriglyceridemia, Cardiovascular Diseases | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 1478 | 2022-11-21 | 2026-02-10 |
| A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Olezarsen, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 446 | 2022-08-31 | 2025-10-22 |
| A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen Olezarsen - Familial Chylomicronemia Syndrome | Phase 3 | Active not recruiting | Ionis Pharmaceuticals, Inc. | 24 | 2022-02-25 | 2025-12-12 |
| A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) Olezarsen - Familial Chylomicronemia Syndrome | Phase 3 | Active not recruiting | Ionis Pharmaceuticals, Inc. | 60 | 2021-11-18 | 2025-12-12 |
| A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia Olezarsen, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 617 | 2021-10-25 | 2026-02-10 |
| A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) Olezarsen, Placebo - Familial Chylomicronemia Syndrome | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 66 | 2020-11-18 | 2025-03-06 |
Familial hyperchylomicronemia syndrome (4) · Hypertriglyceridemia (4) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Hyperlipidemias (1) · Metabolic Diseases (1)
Ionis Pharmaceuticals, Inc. (8)
United States (8) · Canada (7) · France (6) · Italy (6) · Netherlands (6) · Portugal (6) · Slovakia (6) · Spain (6) · Sweden (6) · Norway (5) · Bulgaria (4) · Czechia (4) · Hungary (4) · Poland (4) · United Kingdom (4)
PMID 40064331, PMID 41211918, PMID 38587247, PMID 40081744, PMID 40888739, PMID 41545246, PMID 41910513
2023 (1)